This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory



Wyeth Enters Into Collaborative Research Agreements

On February 5, 2007, Wyeth Pharmaceuticals announced signing separate research collaboration agreements with two biotechnology companies to develop new recombinant factor therapies to treat hemophilia.


Nautilus Biotech, based in Evry, France, signed a research collaboration and license agreement with Wyeth to discover and develop novel recombinant factor IX (rFIX) proteins to treat hemophilia B. It will apply its patented technology, which makes minimal and specific changes to amino acid sequences in order to slow the breakdown of rFIX. The companies want to find a way to help FIX stay active in the body longer, extending its half-life and, consequently, reducing the number and frequency of infusions in patients.


Wyeth agreed to develop, manufacture and market any products derived from the collaborative research. Nautilus will receive an upfront payment, research and development fees, and milestone payments from Wyeth associated with development, regulatory filings and approvals, and royalty payments based on net sales of products. 


“Wyeth has an impressive track record as a pioneer in developing state-of-the-art hemophilia therapies and Nautilus Biotech has a unique technology for improving protein medicines,” said Manuel Vega, Nautilus’ chief executive officer. “We believe that the collaboration between Wyeth and Nautilus will offer exciting new therapeutic approaches for hemophilia,”


The second company, MediVas, LLC, located in San Diego, signed a research collaboration with Wyeth to discover, develop, manufacture and commercialize new biopharmaceutical products that extend the half-life of recombinant factor therapies for hemophilia. It will employ its patented, polymer-based drug delivery system to create improved delivery methods for Wyeth’s recombinant hemophilia products. The aim of this collaboration is also to prolong the half-life of new hemophilia therapies.


“Our new research collaboration is in keeping with Wyeth’s strong presence in biopharmaceuticals and the history of innovation in hemophilia research. The novel approach of polymer-based delivery systems could offer promise for other therapeutic applications,” said Cavan Redmond, executive vice president and general manager, BioPharma Business Unit at Wyeth Pharmaceuticals.


Source: Wyeth Pharmaceuticals press releases dated February 5, 2007